MedPath
HSA Approval

SODIUM IODIDE NA131I POLATOM CAPSULE

SIN15467P

SODIUM IODIDE NA131I POLATOM CAPSULE

SODIUM IODIDE NA131I POLATOM CAPSULE

April 23, 2018

QUANTUM TECHNOLOGIES GLOBAL PTE. LTD.

QUANTUM TECHNOLOGIES GLOBAL PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantQUANTUM TECHNOLOGIES GLOBAL PTE. LTD.
Licence HolderQUANTUM TECHNOLOGIES GLOBAL PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

CAPSULE

**4.2 Posology and method of administration** Sodium iodide Na131I POLATOM, capsules for therapeutic use is a medicinal product with varying radioactivity, for oral administration. The recommended therapeutic dose is a matter for clinical judgement. This dose should be established individually for each patient. Adults: Treatment of hyperthyroidism and nodular goitre: The activity administered is usually in the range of 200 – 800 MBq but repeated treatment may be necessary. The dose required depends on the diagnosis, the size of the gland, thyroid uptake and iodine clearance. Patients should be rendered euthyroid medically whenever possible before giving radioiodine treatment for hyperthyroidism. For thyroid ablation and treatment of metastases: The administered activities following total or subtotal thyroidectomy to ablate remaining thyroid tissue are in the range of 1850 – 3700 MBq. It depends on the remnant size and radioiodine uptake. In subsequent treatment for metastases, administered activity is in the range 3700 – 11 100 MBq. The therapeutic administration of sodium iodide (131I) capsules in patients with significant renal impairment, in which an activity adjustment is necessary, requires special attention. In order to reduce the absorbed radiation dose to the bladder walls (after high doses used e.g in thyroid tumours treatment), the patient should be encouraged to increase oral fluid intake to have frequent bladder emptying. A low iodine diet in patients prior to therapy will enhance (131I) uptake into functioning thyroid tissue. It is recommended to keep the patient fasted for approximately 2 hours before and after swallowing the capsule for better thyroid uptake. Paediatric population: The use of radioiodine in children and adolescents has to be considered carefully, based upon clinical needs and assessing the risk/benefit ratio in this patient group. The activity to be administered to children and adolescents should be a fraction of the adult dose calculated according to child body weight/age. The therapeutic effect is only achieved after several months.

ORAL

Medical Information

**4.1 Therapeutic indications** This product is used in the treatment of: thyroid nodular goitre, hyperthyroidism in the Graves-Basedow’s disease, autonomic nodule and the toxic multinodular goitre. It is used for the thyroid residue ablation after surgery of differentiated thyroid tumours and in the treatment of iodine-accumulating metastases.

**4.3 Contraindications** Sodium iodide Na131I POLATOM, capsules for therapeutic use must not be used in the following cases: - In women with established or suspected pregnancy or when pregnancy has not been excluded (see section 4.6 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). - Breastfeeding women - Hypersensitivity to the active substance or to any of the excipients.

V10XA01

sodium iodide (131I)

Manufacturer Information

QUANTUM TECHNOLOGIES GLOBAL PTE. LTD.

Narodowe Centrum Badan Jadrowych

Active Ingredients

Sodium iodide Na131I, solution

37-5500 MBq

Sodium iodide

Documents

Package Inserts

Sodium Iodide Na131I Polatom Capsule PI.pdf

Approved: April 23, 2018

Download

Patient Information Leaflets

Sodium Iodide Na131I Polatom Capsule PIL.pdf

Approved: April 23, 2018

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

SODIUM IODIDE NA131I POLATOM CAPSULE - HSA Approval | MedPath